Mumbai based drug maker Lupin Ltd reported 64 per cent increase in its net profit for the fourth quarter of current financial year which stood at Rs 157.4 crore as compared to Rs 95.9 crore in the same period last year.

The company’s total income stood at Rs 1069.1 crore, registering an increase of 36.52 per cent. Sales also surged 39.5 per cent to Rs 3,775.9 crore during the reporting period according to consolidated results.

Dr. Kamal K Sharma, Manging Director, Lupin, said, “We had a very strong year driven by growth and consistent performance across all business segments and markets: a strong business performance in the US, solid domestic growth and increased activity in all key markets."

Mr. Sharma added that the firm has emerged as the best managed company in India’s drug industry, reporting increase in net profit and sales for the 11th consecutive quarter.

The drug maker announced a dividend of Rs 12.50 a share to shareholders and is planning to acquire a firm in West Asia and Latin America. Shares of company surged 1.12 per cent on the Bombay Stock Exchange and closed at Rs 783.6.